Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET
IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025.
Title: |
Mdxhealth Presents First Quarter 2025 Financial Results and Corporate Update Conference Call and Webcast |
Speakers: | Michael K. McGarrity, Chief Executive Officer Ron Kalfus, Chief Financial Officer |
Date: | May 14, 2025 |
Time: | 4:30pm ET/ 22:30 CET |
Conference Call Dial-in Details: | United States: 1-844-825-9789 Belgium: 0800 38 961 The Netherlands: 0800 94 94 506 United Kingdom: 0808 238 9064 |
Conference ID: | 10199102 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1716341&tp_key=092e4b795e |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About Mdxhealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
MDxHealth info@mdxhealth.com |
|
LifeSci Advisors (IR & PR) US: +1 949 271 9223 ir@mdxhealth.com |
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。